Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dermatological complications and safety of anti-TNF treatments.

× No keyword cloud information.

12 in total

Review 1. Safety of biologic therapy in rheumatoid arthritis.

Authors: Robert S Woodrick; Eric M Ruderman
Journal: Nat Rev Rheumatol Date: 2011-10-11 Impact factor: 20.543

Review 2. [What the rheumatologist can learn from the dermatologist-or: nobody can separate good friends : Interfaces of both domains].

Authors: K Schäkel; A Schirra
Journal: Z Rheumatol Date: 2018-08 Impact factor: 1.372

3. Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events.

Authors: Diogo Mendes; Carlos Alves; Francisco Batel Marques
Journal: Clin Rheumatol Date: 2013-04-21 Impact factor: 2.980

Review 4. Adverse reactions to biologic agents and their medical management.

Authors: Onur Boyman; Denis Comte; François Spertini
Journal: Nat Rev Rheumatol Date: 2014-08-12 Impact factor: 20.543

Review 5. Current clinical issue of skin lesions in patients with inflammatory bowel disease.

Authors: Tomoya Iida; Tokimasa Hida; Minoru Matsuura; Hisashi Uhara; Hiroshi Nakase
Journal: Clin J Gastroenterol Date: 2019-03-05

6. Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

Authors: Melissa A Michelon; Alice B Gottlieb
Journal: Clin Cosmet Investig Dermatol Date: 2010-05-25

7. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Authors: Kristine L Stump; Lily D Lu; Pawel Dobrzanski; Cynthia Serdikoff; Diane E Gingrich; Ben J Dugan; Thelma S Angeles; Mark S Albom; Mark A Ator; Bruce D Dorsey; Bruce A Ruggeri; Matthew M Seavey
Journal: Arthritis Res Ther Date: 2011-04-21 Impact factor: 5.156

8. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.

Authors: P Andrade; S Lopes; R Gaspar; A Nunes; S Magina; G Macedo
Journal: Dig Dis Sci Date: 2018-01-18 Impact factor: 3.487

9. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.

Authors: Jan Hillson; Tim Mant; Molly Rosano; Carolyn Huntenburg; Mehrshid Alai-Safar; Siddhesh Darne; Donna Palmer; Borislava G Pavlova; Jennifer Doralt; Russell Reeve; Niti Goel; Doris Weilert; Paul W Rhyne; Kamali Chance; John Caminis; James Roach; Tanmoy Ganguly
Journal: Pharmacol Res Perspect Date: 2018-02

Review 10. Extra-adrenal glucocorticoid biosynthesis: implications for autoimmune and inflammatory disorders.

Authors: Radomir M Slominski; Robert C Tuckey; Pulak R Manna; Anton M Jetten; Arnold Postlethwaite; Chander Raman; Andrzej T Slominski
Journal: Genes Immun Date: 2020-03-23 Impact factor: 2.676